Cost-Effectiveness of Anticoagulation Treatment for Subclinical Device-Detected Atrial Fibrillation
-
By
-
Aleksi K. Winstén
-
Ville Langén
-
K.E. Juhani Airaksinen
-
Konsta Teppo
-
June 8, 2026
-
Clinical Scorecard: Economic Evaluation of Anticoagulant Therapy for Subclinical Atrial Fibrillation Detected by Devices
At a Glance
| Category | Detail |
|---|
| Condition | Subclinical Atrial Fibrillation |
| Key Mechanisms | Anticoagulation for stroke prevention and risk of major bleeding. |
| Target Population | Patients with device-detected subclinical atrial fibrillation, particularly those aged around 77 years. |
| Care Setting | Health system perspective, focusing on direct medical costs. |
Key Highlights
- Anticoagulation modestly reduces stroke risk but increases major bleeding risk.
- Cost-effectiveness of DOAC therapy remains uncertain despite marginal clinical benefits.
- Modeling study utilized a Markov model with a 10-year simulation for 10,000 individuals.
Guideline-Based Recommendations
Diagnosis
- Device-detected atrial fibrillation should be evaluated for potential anticoagulation.
Management
- Consider anticoagulation based on existing clinical practice guidelines for atrial fibrillation.
Monitoring & Follow-up
- Monitor for major bleeding events and adjust therapy as necessary.
Risks
- Increased risk of major bleeding associated with DOAC therapy.
Patient & Prescribing Data
77-year-old patients without prior clinical AF.
Anticoagulation not significantly affecting mortality; focus on stroke and bleeding outcomes.
Clinical Best Practices
- Utilize a health system perspective for cost-effectiveness evaluations.
- Incorporate health-related quality-of-life decrements in treatment assessments.
Related Resources & Content
